Young People and Illness Management and Recovery (IMR)
Young People's Experiences of Illness Management and Recovery (IMR) - an Explorative Study
The study is a combined clinical patient outcome study and a health-services research sub-study. Illness management and recovery (IMR) constitutes an evidence-based practice with 11 modules focusing on personal recovery developed for adults with severe mental health illnesses. IMR can be offered in groups or individually, once a week for 10-12 months.
Little is known about how young people experience the utility of IMR treatment groups in child and adolescent mental health outpatient clinics. The primary aim is to explore in-depth how the participants experience the utility of the IMR approach. The health research sub-study will provide new insights into the IMR implementation process in outpatient clinics for adolescents.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
IMR has previously been implemented for adolescents in an inpatient unit in the hospital's catchment area. In order to offer the same treatment to all young patients, IMR treatment groups will be established in 4 out of 7 outpatient clinics in the hospital's catchment area. Participants belonging to the clinics in which no IMR treatment groups are being established will be invited to participate in IMR groups in clinics nearby.
The primary aim is to gain new insight into how young people experience the utility of IMR treatment groups conducted in outpatient practices and, if relevant, which changes could be made to adapt IMR more to young people. To explore how the participants experience the utility of IMR treatment groups, a qualitative focus-group study, consisting of a maximum of 5 focus-group interviews will be conducted. The participants in each IMR treatment group will be offered treatment once a week up to 10-12 months. To establish an IMR treatment group a minimum of 4 patients and a maximum of 8 participants must participate. Participants are mainly being included in the IMR treatment groups at the two primary admissions to each treatment group. Thus, some of the participants in the focus-groups may have participated in IMR groups for less than 10-12 months.
Secondary outcomes are related to fidelity to the model and the extent to which IMR treatment groups are implemented at an organizational level. The treatment groups will be led by trained IMR-therapists employed in inpatient units, together with therapists in training who are employed in outpatient clinics. Leaders and other clinicians in the outpatient clinics will contribute knowledge about the extent to which core components of IMR are being implemented, as well as information relating to quality improvement and individual adjustment. Two of the out-patient clinics in which no IMR group is being established will be included in the sub-study. The clinics will receive written feedback after each measurement time to support quality improvement.
The goal is to include up to 48 participants receiving IMR treatment in outpatient clinics. Up to 8 hospitalized participants will participate in a pilot focus-group interview. In the sub-study, a maximum of 16 IMR therapists, trained and in training, and up to 24 staff members will be invited to participate.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
-
Viken, Norvège
- Akershus Universitetssykehus
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria Patients:
Outpatient units:
- Included in the IMR group in one of the outpatient clinics
- Able to give informed consent
Inpatient unit (focus group):
- 13-17 years of age
- Current or previous patient
- Able to understand and speak Norwegian
- Able to give informed consent
Exclusion criteria (inpatient unit)
- Younger than 13 years
- Mental retardation
- Manic phase
Inclusion Criteria: IMR therapists:
- IMR therapist leading IMR treatment groups in one of the participating outpatient clinics
- Trained or training in IMR
- Employed at the Department for Child and Adolescent Mental Health Services at Akershus University Hospital.
Inclusion Criteria: Other staff members
• Employed at the Department for Child and Adolescent Mental Health Services at Akershus University Hospital.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
IMR patients
Patients from outpatient clinics receiving IMR from trained IMR therapists and IMR therapists in training.
|
Treatment given in groups, weekly for 10-12 months.
Autres noms:
|
|
IMR therapists and other staff
Clinic leaders, IMR therapists and other staff participating in semi-structured individual or group interviews.
|
Semi-structured individual or group interviews conducted three times with staff on each participating outpatient clinic.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Focus-group interview aiming to explore the significance of the participant's own understanding of and knowledge about the disorder.
Délai: End of treatment group, on average 11 months.
|
Focus-group interviews when the treatment group has come to an end aimed at exploring different perspectives on IMR treatment.
|
End of treatment group, on average 11 months.
|
|
Focus-group interview aiming to explore the impact of the IMR treatment on dealing with everyday life.
Délai: End of treatment group, on average 11 months.
|
Focus-group interviews when the treatment group has come to an end aimed at exploring different perspectives on IMR treatment.
|
End of treatment group, on average 11 months.
|
|
Focus-group interview aiming to explore the importance of meeting other young people in the same situation.
Délai: End of treatment group, on average 11 months.
|
Focus-group interviews when the treatment group has come to an end aimed at exploring different perspectives on IMR treatment.
|
End of treatment group, on average 11 months.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
The Illness Management and Recovery Scale (IMRS)
Délai: Baseline (0 months), 6 and 12 months.
|
A 15-item scale that assesses illness self-management on a 5-point Likert scale where 5 indicates full self-management and 0 indicates no self-management.
The scale measures consumer behavior relating to core components in the IMR program.
The scale includes parallel clinician and consumer versions.
Participants participating in IMR groups for less than 10-12 months will attend fewer measuring times.
|
Baseline (0 months), 6 and 12 months.
|
|
The Illness Management Fidelity Scale
Délai: Baseline (0 months), 6 and 12 months.
|
Assesses the degree of fidelity with 13 items on a 5-point Likert scale where 5 indicates full implementation and 0 indicates no implementation.
Filled in by researchers on the basis of a semistructured interview with staff members.
|
Baseline (0 months), 6 and 12 months.
|
|
General Organizational Index
Délai: Baseline (0 months), 6 and 12 months.
|
A 12-item scale measuring organizational outcome of implementation, on a 5-point Likert scale where 5 indicates full implementation and 0 indicates no implementation.
The scale is filled in by researchers on the basis of a semi-structured interview with staff members.
|
Baseline (0 months), 6 and 12 months.
|
|
Attendance registration
Délai: Baseline (0 months), 3, 6, 9 and 12 months.
|
The number of sessions the patients are attending in the IMR treatment group.
|
Baseline (0 months), 3, 6, 9 and 12 months.
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Mapping the total number of patients identified receiving a psychosis-related diagnosis within the categories F 20-39 (ICD 10) for the years 2021-2023.
Délai: End of treatment group, on average of 11 months.
|
The numbers will be displayed in the form of statistics obtained in the hospital.
The numbers will be compared to what has been reported in the annual reports for the clinics from 2015 to 2020.
|
End of treatment group, on average of 11 months.
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Anne-Lise Holmesland, PhD, University Hospital, Akershus
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 20/09657
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .